AstraZeneca PLC (AZN)vsElutia Inc. (ELUT)
AZN
AstraZeneca PLC
$166.08
+1.22%
HEALTHCARE · Cap: $257.57B
ELUT
Elutia Inc.
$0.85
+0.40%
HEALTHCARE · Cap: $35.87M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 505553% more annual revenue ($61.37B vs $12.14M). ELUT leads profitability with a 426.9% profit margin vs 17.0%. AZN earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
ELUT
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+15.2%
Fair Value
$195.81
Current Price
$166.08
$29.73 discount
Margin of Safety
-0.0%
Fair Value
$0.90
Current Price
$0.85
$0.05 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Every $100 of equity generates 221 in profit
Keeps 427 of every $100 in revenue as profit
Reasonable price relative to book value
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
Revenue declined 11.6%
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.19 suggests the stock is reasonably priced for its growth.
Bull Case : ELUT
The strongest argument for ELUT centers on Return on Equity, Profit Margin, Price/Book. Profitability is solid with margins at 426.9% and operating margin at -243.1%.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : ELUT
The primary concerns for ELUT are EPS Growth, Market Cap, Revenue Growth.
Key Dynamics to Monitor
AZN profiles as a mature stock while ELUT is a declining play — different risk/reward profiles.
ELUT carries more volatility with a beta of 0.88 — expect wider price swings.
AZN is growing revenue faster at 6.4% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 35/100), backed by strong 17.0% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Elutia Inc.
HEALTHCARE · MEDICAL DEVICES · USA
Elutia Inc., a commercial-stage company, engages in developing and commercializing drug-eluting biomatrix technology to enhance surgical outcomes. The company is headquartered in Silver Spring, Maryland.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?